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Abstract
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Homozygous and compound heterozygous mutations in SLC34A3, the gene encoding the sodiumdependent co-transporter NaPi-IIc, cause hereditary hypophosphatemic rickets with hypercalciuria
(HHRH), a disorder characterized by renal phosphate-wasting resulting in hypophosphatemia,
elevated 1,25(OH)2 vitamin D levels, hypercalciuria, rickets/osteomalacia, and frequently kidney
stones or nephrocalcinosis. Similar albeit less severe biochemical changes are also observed in
heterozygous carriers, which are furthermore indistinguishable from those encountered in
idiopathic hypercalciuria (IH). We now searched for SLC34A3 mutations (exons and introns) in
two previously not reported HHRH kindreds, which resulted in the identification of three novel
mutations. The affected members of kindred A were compound heterozygous for two different
mutations, c.1046_47del and the intronic mutation c.560+23_561-42del, while the index case in
kindred B was homozygous for the nonsense SLC34A3 mutation c.1764C>G (p.Y588X). The
patient in kindred C was diagnosed with IH because of bilateral medullary nephrocalcinosis,
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suppressed PTH levels, and hypercalciuria; she was found to have a novel heterozygous c.
1571_1880del mutation. The HHRH patients in kindred A were treated for up to 7 years with oral
phosphate, which led to reversal of hypophosphatemia, hypercalciuria, and prevention or healing
of the mild bone abnormalities. PTH levels were normal throughout the observation period, while
1,25(OH)2 vitamin D levels remained elevated and may thus be helpful for assessing treatment
efficacy and patient compliance in HHRH.

1. INTRODUCTION
Phosphate is essential for numerous cellular processes, DNA synthesis, and it is part of
structural hydroxyapatite, thereby providing strength to the skeleton, which furthermore
serves as a reservoir for this mineral [1]. Intestinal phosphate absorption occurs through
paracellular, as well as active transcellular mechanisms involving the sodium-dependent
phosphate co-transporter NaPi-IIb (SLC34A2) [2,3]. In the proximal tubules of the kidney,
two closely related transporters, namely NaPi-IIa (SLC34A1) [4] and NaPi-IIc (SLC34A3)
[5] reabsorb more than 70% of filtered phosphate. Expression of both transporters at the
brush border membrane is directly or indirectly influenced by two phosphaturic hormones,
parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23), and possibly by the
biologically active form of vitamin D, 1,25(OH)2 vitamin D [6].
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NaPi-IIa and NaPi-IIc functions have been extensively studied through different in vitro and
in vivo approaches. For example, studies in rodents have shown that injection of PTH
rapidly reduces expression of NaPi-IIa and with some delay NaPi-IIc [7], while FGF23
requires several hours before a significant decrease in serum phosphate levels can be
observed [8,9]. Furthermore, 1,25(OH)2 vitamin D was previously shown to regulate
expression of NaPi-IIa in juxtamedullary kidney cortex, but not in the superficial cortex [6];
the role of 1,25(OH)2 vitamin D in the regulation of NaPi-IIc has not yet been investigated.
Although the ablation of NaPi-IIc provided no clear evidence for a role of this transporter in
renal phosphate handling [5], the combined ablation of NaPi-IIa and NaPi-IIc revealed that
both transporters have an important role in maintaining rodent serum phosphorus levels
within normal limits [10].
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However, most significant insights into the importance of NaPi-IIc in human phosphate
homeostasis were obtained by revealing that inactivating mutations on both parental alleles
are the cause of hereditary hypophosphatemic rickets with hypercalciuria (HHRH; OMIM:
241530) [11-13]. HHRH was first defined as a distinct disorder when Tieder et al. reported a
Bedouin kindred, in which consanguinity suggested an autosomal recessive mode of
inheritance [14,15]. Individuals affected by HHRH, who carry homozygous or compound
heterozygous NaPi-IIc mutations, show increased urinary phosphate excretion leading to
hypophosphatemic rickets, bowing, and short stature, as well as elevated 1,25(OH)2 vitamin
D levels leading to hypercalciuria because of enhanced intestinal absorption of calcium and
reduced PTH-dependent calcium-reabsorption in the distal renal tubules. Heterozygous
NaPi-IIc mutations are frequently associated with hypercalciuria, but none of the
heterozygous carriers of the originally described HHRH patients had renal calcifications and
kidney stones [14,15]; subsequent investigations, however, revealed renal complications in
numerous patients with homozygous or compound heterozygous NaPi-IIc mutations
[13,16-21]. The presence of kidney stones or nephrocalcinosis in HHRH kindreds is
different from the findings in FGF23-dependent hypophosphatemic disorders such as Xlinked hypophosphatemia (XLH; mutant PHEX) [22], autosomal dominant
hypophosphatemia (ADHR; mutant FGF23) [23], or autosomal recessive hypophosphatemia
(ARHR; mutant DMP1 or ENPP1) [24-26], in which affected individuals show
inappropriately normal or suppressed 1,25(OH)2 vitamin D levels despite significant
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hypophosphatemia and thus no increase in urinary calcium excretion (at least prior to
treatment with oral phosphate) [12,27].
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Based on the underlying molecular defect that results in an FGF23-independent increase in
urinary phosphate excretion, HHRH is thought to require a different therapeutic approach
than FGF23-dependent hypophosphatemic disorders such as XLH. While oral phosphate
supplements in combination with active vitamin D analogs are generally required for the
treatment in the latter disorder [28], treatment with phosphate supplements alone is deemed
sufficient for individuals with HHRH [14,15]; particularly since endogenously elevated
1,25(OH)2 vitamin D levels are predicted to prevent an increase in PTH secretion triggered
by intermittent elevations in serum phosphate. In fact, therapy of HHRH patients with oral
phosphate alone raises blood phosphate levels and is generally successful in resolving acute
symptoms and abnormal bone mineralization, but no long-term follow-up studies exist
evaluating the efficacy of this therapeutic approach. Despite persistent hypophosphatemia,
phosphate treatment usually also leads to an improvement of the rachitic bone changes in
XLH, yet it is well established that these patients often develop secondary or tertiary
hyperparathyroidism when treated with oral phosphate alone [29]. Similar data evaluating
outcomes in HHRH are lacking and it is conceivable that long-term oral phosphate
supplementation of HHRH patients may affect parathyroid function and/or increase the risk
for the development of nephrocalcinosis and kidney stones by increasing the urinary
phosphate load, even if treatment with activated vitamin, which may worsen the degree of
hypercalciuria, is avoided [16,18,30].
We here describe two previously not reported HHRH kindreds, in whom we discovered
novel homozygous and compounded heterozygous NaPi-IIc mutations. Occurrence of renal
calcifications as the initial finding in a third unrelated patient with a heterozygous NaPi-IIc
mutation strengthens previous observations suggesting an increased risk for
nephrocalcinosis and renal stones in this population. Follow-up of the three affected
members in one of these families allowed us to assess the efficacy of standard oral
phosphate supplementation with regard to skeletal and laboratory findings.

2. METHODS
2.1. Laboratory Assays

NIH-PA Author Manuscript

With the exception of genetic analyses, all laboratory studies were performed at local
laboratories (normal ranges are provided in parenthesis after each value). Initial laboratory
tests were done for each patient before oral phosphate supplements were administered. The
25(OH) vitamin D levels were measured by liquid chromatography with tandem mass
spectroscopy or chemiluminescence immunoassay, 1,25(OH)2 vitamin D levels by
radioimmunoassay or enzyme-linked immunoassay. Serum intact PTH levels were
determined by electrochemiluminescence immunoassay and FGF23 level were measured by
c- terminal FGF23 ELISA (Immutopics, San Clemente, CA). The renal tubular reabsorption
of phosphorus was calculated using the following formula: %TRP = 100 × (1 - (urine
phosphorus × serum creatinine)/(serum phosphorus × urine creatinine); when serum
phosphorus is below the reference range for age, %TRP should be above 90. TmP/GFR was
estimated using the Walton and Bijvoet nomogram [31,32].
2.2. SLC34A3 genetic analysis
Mutational and haplotype analysis of SLC34A3 was performed after informed written
consent was obtained using forms approved by the institutional review board of
Massachusetts General Hospital. The entire SLC34A3 gene, including approximately 800 bp
5′ of the transcriptional start site, all intervening sequences and approximately 200 bp of the
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3′ UTR, was amplified by PCR from genomic DNA of the index cases (A/II-3, B/II-2, C/
II-3), followed by nucleotide sequence analysis at the Massachusetts General Hospital DNA
Sequencing Core Facility or at Genewiz Inc. (Cambridge, MA). PCR assays to confirm the
findings in index cases and to analyze family members and controls were designed as
described [11,12] using Qiagen reagents (Valencia, CA) at standard PCR cycling conditions.
The following primers were used for c.1046_47del: 5′-CTCTGACCTCTGTCTGCC-3′ and
5′-GGAAGGGGAAGTCTATGG-3′, followed by nucleotide sequence analysis; for c.
560+23_561-42del: 5′-AGCATGGTGGCTGCTAAGC-3′ and 5′GGGTGTCAGGCTGGCGGC-3′, and for c.1571_1880del: 5′CATCCACTTCTTCTTCAACCTG-3′ and 5′-CCATTCCTTGGGAGCTTC-3′, both latter
amplicons were separated by 3% agarose TAE gel electrophoresis to detect mutant alleles
that are shortened by 30 and 310 bp, respectively. The primers for c.1764C>G were 5′GCTCCTTCTGTAGGGTGGAG-3′ and 5′-AAGCAGGTGACCGGAGG-3′, followed by
restriction enzymatic digestion with Bfa1, resulted in the generation of two fragments (520
bp and 142 bp, respectively), whereas the PCR product derived from the wild-type allele
revealed a single band of 662 bp.
Searches of NCBI-dbSNP [33] and the 1000 genomes project [34] were negative for the
identified mutations. GenBank accession numbers for SLC34A3 are as follows: genomic
contig NT_024000.15; cDNA, NM_080877.1; protein, NP_543153.1.
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3. RESULTS
3.1. Kindred A
The 8 year old index case A/II-3 was referred to S.R.S. for evaluation of bowed legs. With
the exception of an uncomplicated clavicular fracture as a toddler, childhood development
was within normal limits. Physical examination confirmed genu valgum without evidence
for pain or swelling, but revealed no additional skeletal findings.
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The initial laboratory testing (Fig. 1) showed a low serum phosphorus level of 1.17 mmol/L
(1.45-1.78 mmol/L) and an elevated alkaline phosphatase of 496 U/L (86-315 U/L) with
normal serum calcium, creatinine, PTH and 25(OH) vitamin D levels. Despite
hypophosphatemia, tubular reabsorption of phosphate (TRP) was decreased at 75% (>90%)
and the maximal renal phosphate reabsorption per glomerular filtration rate (TmP/GFR) was
low at 0.86 mmol/L (1.51-2.18 mmol/L), which was consistent with renal phosphate
wasting. Inappropriately low tubular reabsorption of phosphate along with an appropriately
elevated 1,25(OH)2 vitamin D level of 260 pmol/L (40-140 pmol/L) raised the suspicion for
HHRH. A subsequently obtained 24-hour-urine collection showed an elevated level of
urinary calcium excretion (0.13 mmol/kg/day; normal: 0.05-0.1 mmol/kg/day); the urinary
calcium/creatinine ratio was elevated at 0.97 mmol/mmol (0.03-0.71 mmol/mmol). Urine
analysis showed no evidence for glucose, protein, or amino acids; serum bicarbonate level
was within normal limits. Radiographs of both knees revealed valgus deformity and
generalized osteopenia with numerous transversely oriented reinforcement lines in the
medullary portions of the distal femora and proximal tibiae, as evidence for previous
intermittent mineralization defects (Suppl. Fig. 1).
Laboratory investigations of the patient’s four siblings were conducted, which revealed no
abnormalities for his sister (A/II-1) and one of his brothers (A/II-2). The affected brothers,
A/II-4 and A/II-5, were asymptomatic and showed no evidence for bowing. Radiographic
evaluation, however, revealed multiple growth arrest lines and demineralization consistent
with hypophosphatemic rickets. Both children showed biochemical abnormalities including
hypophosphatemia, hypercalciuria, and increased 1,25(OH)2 vitamin D levels (Fig.1). The
non-consanguineous parents were found to be healthy and their laboratory results were
Bone. Author manuscript; available in PMC 2013 May 1.
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within normal limits, with the exception of a slightly reduced serum phosphorus level of the
father (0.82 mmol/L; normal: 0.85-1.52 mmol/L).
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Treatment of A/II-3 with oral phosphate supplements (250 mg bid; 20 mg/kg/day) was
started at the age of 91/12 years; the dose was slowly increased to 40 mg/kg/day (divided into
three doses). Similar treatment was initiated for A/II-4 and A/II-5, which led to
normalization of serum phosphorus levels and urinary calcium excretion in all three
children; PTH and 25(OH) vitamin D remained within normal limits. Conversely,
1,25(OH)2 vitamin D levels remained elevated in all three individuals (Fig. 2A-F), while
alkaline phosphatase activity normalized in A/II-4 and A/II-5, but increased during puberty
in A/II-3. After improving serum phosphorus levels, A/II-3 showed some catch-up growth
from the 3rd to the 25th percentile; if growth continues along this percentile he would reach
the mid-parental height. There was no change in growth velocity for A/II-5, who continued
growth along the 3rd percentile after oral phosphate supplements had been started. A/II-4
showed only mild improvement in growth velocity; 5th to the 10th percentile (data not
shown). No episodes of hematuria were reported for the three affected members and
screening by renal ultrasound showed no evidence for nephrolithiasis.
3.2. Kindred B
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The index case (B/II-2) was evaluated for non-specific bone pain in her native country as a
toddler. After immigrating at the age of 5 years with her family to the United States of
America, she again came to medical attention for bilateral genu valga. At the age of 7 years,
laboratory evaluation revealed hypophosphatemia, decreased 25(OH) vitamin D levels, and
elevated alkaline phosphatase levels. At the age of 8 years, an eight-plate was placed to
correct alignment without compressing the growth plate, and was removed one year later.
She was initially treated with ergocalciferol and calcium carbonate for suspected vitamin D
deficiency, which resulted in normalization of her 25(OH) vitamin D levels, but did not
correct her hypophosphatemia. When she was referred at the age of 11 years to N.D.,
hypercalciuria was noted leading to the presumptive diagnosis of HHRH and she was started
on 1000 mg K-Phos tid.
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The patient’s maternal great-grandmother and paternal grandfather were siblings. Her
father’s height is 172.7 cm, he has no evidence for bowed legs and no history of bone pain,
but had previously passed a calcium oxalate stone. Laboratory investigations showed a low
serum phosphorus level (0.74 mmol/L; normal: 0.81-145 mmol/L), low 25(OH) vitamin D
(21 nmol/L; normal: 80-250 nmol/L) and decreased TRP (81.4%, normal: >90%) as well as
a low TmP/GFR of 0.6 mmol/L (0.63-1.32mmol/L). The patient’s mother is healthy, her
height is 165.1 cm and she has no history of bone or kidney disease; the two siblings of B/
II-2 showed some biochemical abnormalities (Fig. 1).
At presentation to our hospital (A.S.) she was 124/12 years old, her height was 152.4 cm
(54th percentile) and her weight 74 kilogram (>97th percentile). Physical examination
revealed no bony abnormalities for the upper extremities with normal range of motion and
strength, but the lower extremities showed scars from prior surgery and marked genu
valgum with intramedullary distance of 12 cm. A renal ultrasound was significant for
nephrocalcinosis (data not shown).
Laboratory evaluation revealed a low serum phosphorus level of 0.97 mmol/L (1.23-1.62
mmol/L) and an elevated alkaline phosphatase level of 470 U/L (15-350 U/L). Her
1,25(OH)2 vitamin D level was elevated to 294 pmol/L (62-224 pmol/L), while the 25(OH)
vitamin D level was at 30 nmol/L (82-250 nmol/L). Serum calcium, PTH, and creatinine
were within normal limits, as was c-terminal FGF23 (68 RU/ml; normal: <230 RU/ml).
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Urine analysis revealed a TRP of only 56.6% (>90%) and a low TmP/GFR of 0.75 mmol/L
(1.14-2.13 mmol/L). The urinary calcium/creatinine ratio was slightly elevated at 0.71
mmol/mmol (0.03-0.68 mmol/mmol), but there was no evidence for generalized tubular
dysfunction as indicated by the lack of proteinuria, glucosuria, or aminoaciduria, and a
normal serum bicarbonate level.
3.3. Kindred C
The index case (C/II-3) was referred to T.S. at the age of 710/12 years, because of abdominal
pain over the flank area for the past year, which prompted ultrasonographic studies revealing
bilateral medullary nephrocalcinosis (Suppl. Fig. 2). Her history was otherwise
unremarkable except for increased urinary frequency and mild asthma. There was no history
of macroscopic hematuria, passage of stones/gravel or urinary tract infection. The family
history was significant for the maternal grandfather being diagnosed with kidney stones and
Crohn’s disease; other members of the father’s family had been diagnosed with what was
referred to as “nephritis”. The older brother was found to have hypercalciuria when he was
evaluated for discomfort with urination two years prior to the presentation of the index case;
subsequent evaluations showed normal urinary calcium excretion. Both parents and the
older sister are healthy without urinary symptoms, stones, osteopenia and/or bone fractures.
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The patient’s height at presentation was 123.9 cm (30th percentile), weight 23.6 kg (34th
percentile), and BMI 15.4 kg/m2. Laboratory studies revealed normal levels for calcium,
phosphorus, alkaline phosphatase, creatinine, 1,25(OH)2 vitamin D and 25(OH) vitamin D.
PTH was below the normal range (0.6 pmol/L; normal: 0.7-7.5 pmol/L) and c-terminal
FGF23 was within the normal range (109 RU/ml; normal: <230 RU/ml). The urinary
calcium/creatinine ratio was elevated at 0.93 mmol/mmol (0.03-0.71 mmol/mmol), TRP was
86% (>90% in the setting of hypophosphatemia) and TmP/GFR was at the lower end of the
normal range at 1.5 mmol/L (1.45-2.46 mmol/L). A 24-hour urine collection with
simultaneous blood evaluation for nephrocalcinosis made primary hyperoxaluria, Dent’s
disease, renal tubular acidosis, hypophophatasia, and an activating mutation in calciumsensing receptor unlikely; familial hypomagnesemia with hypercalciuria as the cause of
nephrocalcinosis was equally unlikely. The patient’s hypercalciuria was treated
symptomatically with Amiloride and potassium citrate. On this therapy her laboratory
studies were: calcium, 2.55 mmol/L; phosphorus, 1.71 mmol/L; magnesium, 0.9 mmol/L;
bicarbonate, 29 mmol/L; alkaline phosphatase, 241 U/L; creatinine, 61.9 μmol/L; 1,25(OH)2
vitamin D, 120 pmol/L; and 25(OH) vitamin D, 130 nmol/L. The serum PTH was at the
lower end of the normal range with 1.5 pmol/L (1.5-6.5 pmol/L). The repeat TRP
measurement was 76%, a fasting TmP/GFR was low at 1.2 mmol/L (1.45-2.46 mmol/L).
The urinary calcium/creatinine ratio was elevated at 0.76 mmol/mmol (0.03-0.71 mmol/
mmol) with an excretion of 0.12 mmol/kg/day. The renal ultrasound revealed no change in
the medullary nephrocalcinosis. The increase in urine phosphorus excretion despite a low
serum PTH level, associated with an 1,25(OH)2 vitamin D at the upper end of the normal
range and increased urine calcium excretion led us to search for a defect in one of the
sodium-phosphate co-transporters.
3.4. Mutational Analysis
Mutational analysis of the SLC34A3 gene for individuals A/II-3, A/II-4 and A/II-5 revealed
compound heterozygosity for two novel mutations: c.1046_47del and c.560+23_561-42del
(Fig. 1). c.1046_47del leads to a frame-shift in exon 10 of SLC34A3, while the
consequences of c.560+23_561-42del in intron 6 are uncertain, but may involve alternative
splicing as has been reported for other intronic SLC34A3 deletions [13]. c.1046_47del was
inherited from the healthy mother A/I-2, while c.560+23_561-42del was inherited from the
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father A/I-1. The unaffected siblings A/II-1 and A/II-2 are each carriers of either one of the
two mutations.
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Consistent with consanguinity of her parents, patient B/II-2 was found to be homozygous for
a novel missense mutation in exon 13 (c.1764C>G; p.Y588X) (Fig. 1), which prematurely
terminates the open reading-frame 12 amino acids before the natural termination codon. The
c.1764C>G p.Y588X nucleotide change introduces a novel Bfa1 endonuclease restriction
site, which permitted confirmation of the results obtained by nucleotide sequence analysis
and showed that her parents and her two siblings are heterozygous carrier of the mutation.
B/II-2 was furthermore homozygous for several known single nucleotide polymorphisms
throughout SLC34A3 (Suppl. Fig. 3).
Patient C/II-3 revealed a novel heterozygous deletion of 310 bp in exon 13 (c.
1571_1880del), but no evidence for a mutation on the second allele. c.1571_1880del is
predicted to change the NaPi-IIc co-transporter protein after amino acid residue 523,
followed by 13 unrelated amino acids and a termination codon. The deletion was also
identified in her father C/I-2. Several known heterozygous and homozygous polymorphisms
were found throughout the gene (Suppl. Fig. 3). One of the heterozygous polymorphisms
(rs34372115; c.200G/A), which changes arginine 67 to histidine (R67H), has a minor allele
frequency of only 8.6-15% [34] and thus could have represented the second mutation;
however, it was inherited paternally on the same allele as c.1571_1880del.
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4. DISCUSSION
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The index cases in kindreds A and B showed hypophosphatemia due to increased urinary
phosphate excretion, normal calcium, and normal or suppressed PTH levels, thus excluding
hyperparathyroidism. In response to the hypophosphatemia, 1,25(OH)2 vitamin D levels
were appropriately increased and normal FGF23 levels made FGF23-dependent causes of
increased urinary phosphate excretion unlikely. Furthermore, urinary calcium excretion was
increased, presumably because of 1,25(OH)2 vitamin D-mediated enhanced intestinal
calcium absorption, but there was no evidence for generalized renal tubular defects, i.e.
metabolic acidosis, aminoaciduria, glucosuria, or hematuria. Based on the laboratory and
radiographic findings, the diagnosis of HHRH was considered and confirmed through the
identification of previously not reported mutations in SLC34A3/NaPi-IIc that are predicted
to affect co-transporter function and thus likely lead to impaired phosphate reabsorption in
the renal proximal tubules. The identified SLC34A3/NaPi-IIc mutations co-segregate with
biochemical and clinical abnormalities in the respective kindreds and were not found in
publically available SNP databases, including the 1000 genomes project, making it likely
that these are the causes of HHRH.
In family A, we discovered two novel compound heterozygous mutations: c.1046_47del and
c.560+23_561-42del, which are predicted to severely alter or abolish NaPi-IIc function. One
of the two mutations, c.560+23_561-42del, deletes 30 bp in intron 6, which may result in
abnormal spliceosome assembly [35], and may lead to non-sense mediated decay of the
mRNA, as has been described previously for deletions in intron 9 and 10 [13]. The change
in open reading frame caused by the second mutation, c.1046_47del, introduces 242 novel
amino acid residues in the C-terminal portion, which have no homology with proteins in the
RefSeq database and likely impair function of the NaPi-IIc co-transporter, or lead to nonsense mediated decay of the mRNA. Likewise, the homozygous mutation c.1764C>G
(p.Y588X) in exon 13 found in the index case of kindred B, most likely provides a
molecular explanation for her HHRH. This mutation changes tyrosine at position 588 at the
C-terminal end to a termination codon thus deleting the terminal 12 amino acids of the cotransporter protein. The equivalent C-terminal portion of the closely related NaPi-IIa
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contains a class 1 PDZ binding domain (TRL), which interacts with several sodium
hydrogen exchange regulatory factors (NHERF) [36-39]. Although NaPi-IIc lacks a PDZ
binding domain, interaction with NHERF1 and NHERF3 has been reported, raising the
possibility that the identified mutation impairs this interaction [40,41]. Functional evaluation
of c.1764C>G (p.Y588X) in Xenopus oocytes has not been performed, but a mutation
(p.V446Stop) that we recently reported in an unrelated kindred leads to a complete loss of
[P32]-transport in support of this conclusion [19].
The deletion of 310 bp in exon 13, c1571_1880del detected in C/II-3, is predicted to cause a
frame-shift and thus likely results in a truncated and presumably nonfunctional protein or in
non-sense mediated decay of the mRNA. This deletion was identified on the paternal allele,
while there was no evidence for a second mutation on the maternal allele. Consistent with
the lack of a second mutation, patient C/II-3 showed only hypercalciuria and biochemical
findings suggestive of a PTH- and FGF23-independent renal phosphate leak.
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Kindred A further supports the notion that HHRH is frequently caused by compound
heterozygous NaPi-IIc mutations. This suggests either that SLC34A3/NaPi-IIc has a high
mutation frequency or that heterozygous carrier status may be relatively frequent in the
population, as also illustrated in C/II-3 and other previously described patients
[13,16,18-21,30]. The subtle proximal tubular abnormalities associated with heterozygous
carrier status in the original Bedouin kindred were initially not thought to increase the risk
for kidney stones [13]. However, several heterozygous carriers of SLC34A3 mutations in
subsequently investigated HHRH kindreds revealed kidney stones, nephrolithiasis, and/or
increased urinary calcium excretion, similar to the findings in C/II-3 [16,18,30]. At least
certain heterozygous SLC34A3 mutations may thus increase the relative risk for developing
nephrocalcinosis and/or kidney stones, which frequently occur in the general population.
Alternatively, it is possible that a SLC34A3 mutation was missed for C/II-3 on the second
allele, or that other genetic modifiers of renal phosphate handling, for example NHERF-1 or
SLC34A1/NaPi-IIa, carry additional nucleotide sequence variations in this individual.
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Improvement of rachitic changes in XLH are often observed despite persistent
hypophosphatemia, while oversupplementation or treatment with oral phosphate alone may
cause secondary or tertiary hyperparathyroidism [29]. Likewise in HHRH patients therapy
with oral phosphate supplements alone is generally effective in resolving bone pain and
abnormal mineralization, and it was shown to reverse most biochemical abnormalities,
except the decrease in TmP/GFR [14]. However, there are no long-term studies
documenting that treatment of HHRH patients with oral phosphate alone is efficacious and
safe. In fact, it is unknown whether secondary hyperparathyroidism can develop as reported
in FGF23-dependent renal phosphate-wasting disorders such as XLH [42], whether
1,25(OH)2 vitamin D levels or other parameters remain abnormal in this group of patients,
or whether an increased urinary phosphate load can lead to renal calcifications.
Based on biochemical follow-up data that were available for the affected members in
kindred A (A/II-3, A/II-4 and A/II-5), oral phosphate supplement resulted in normalization
of serum phosphorus and urine calcium levels, while there was no evidence for the
development of secondary hyperparathyroidism over the course of up to 7 years. Alkaline
phosphatase levels normalized in A/II-4 and A/II-5 over the course of therapy, but improved
only partially in A/II-3 and increased during pubertal development, which could be
indicative of skeletal growth, since catch-up growth and follow-up X-rays suggest that his
rickets had healed. Despite improvement of most abnormalities with oral phosphate
treatment, all three affected siblings had persistently elevated 1,25(OH)2 vitamin D levels. It
is therefore conceivable that higher daily doses and/or more frequent administration of
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phosphate are needed to suppress the 1-alpha-hydroxylase and/or that our patients were not
fully compliant with their supplements.
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To monitor compliance with oral phosphate supplements, measurement of 24 hour urinary
phosphate excretion is usually performed; this requires, however, considerable cooperation
of the often pediatric patients. In HHRH patients, 1,25(OH)2 vitamin D levels are typically
elevated because hypophosphatemia increases renal 1-alpha-hydroxylase activity without
abatement by elevated FGF23 levels. In fact, FGF23 levels should be suppressed due to the
primary renal defect in SLC34A3/NaPi-IIc, which is responsible for increased urinary
phosphate excretion in HHRH; however, current FGF23 assays are not sufficiently sensitive
to distinguish normal from suppressed levels. Our observations in kindred A thus suggest
that measurement of 1,25(OH)2 vitamin D levels, a widely available test, can be helpful for
monitoring therapy and compliance. Since 1,25(OH)2 vitamin D stimulates FGF23
production, which could lead to a further increase in urinary phosphate excretion,
normalization of this parameter may be an important goal and further improve outcomes.
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In summary, we have identified four novel mutations in SLC34A3/NaPi-IIc in two unrelated
HHRH kindreds and a case of IH with bilateral nephrocalcinosis. Follow-up of the three
affected cases in kindred A suggests that sole therapy with oral phosphate supplements
resolved or improved hypophosphatemia, hypercalciuria, and prevented progression or
development of skeletal abnormalities without increasing PTH levels. In the absence of
other biomarkers, 1,25(OH)2 vitamin D levels may be a helpful laboratory parameter for
assessing the treatment efficacy and compliance.
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HIGHLIGHTS
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➢

Three novel NaPi-IIc/SLC34A3 mutations causing HHRH and one novel
mutation in this gene causing IH

➢

Long-term follow up during treatment with oral phosphate

➢

Persistent elevation of 1,25(OH)2 vitamin D levels
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Fig. 1. Laboratory findings in patients with hereditary hypophosphatemic rickets with
hypercalciuria (HHRH) or idiopathic hypercalciuria (IH) caused by novel SLC34A3 utations
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Biochemical parameters for the index cases in kindreds A, B, and C were measured at the
indicated ages before therapy was initiated. Age-related reference ranges in parentheses
(*http://www.mayomedicallaboratories.com/,
°http://cclnprod.cc.nih.gov/dlm/testguide.nsf/Index/
1D336E0232533D3285256B9C0059ECEA, and respective clinical laboratories); agerelated reference ranges for TmP/GFR and Ca/Cr are from [43] and [44], respectively. All
abnormal values are shown in bold. Circles denote females, squares denote men. Black
symbols indicate affected individuals, who presented with hypophosphatemia,
hypercalciuria, elevated 1,25(OH)2 vitamin D levels, and skeletal findings consistent with
rickets, while grey symbols indicate affected individuals, who had one or more of the above
biochemical abnormalities. Open symbols indicate healthy individuals.
Abbreviations are as follows:
ALP, alkaline phosphatase; Ca/Cr= urinary calcium/creatinine ratio; n.d., not determined;
PTH; parathyroid hormone; TmP/GFR, maximum tubular phosphate reabsorption per
glomerular filtrate; TRP, tubular phosphate reabsorption; 1,25(OH)2D, 1,25(OH)2 vitamin
D; 25(OH)D, 25(OH) vitamin D
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Fig. 2. Long-term follow-up of several laboratory parameters for the affected members in
kindred A (II-3, II-4, and II-5)

Serum phosphate (panel A); alkaline phosphatase (panel B), 1,25(OH)2 vitamin D (panel C),
urinary calcium/creatinine ratio (panel D), parathyroid hormone (panel E), and 25(OH)
vitamin D (panel F).
Grey areas indicate normal range, age-matched where indicated. Open circles, A/II-3; closed
squares, A/II-4; open triangles, A/II-5.
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